Scarica l'app Stockscreener
51.91
1.01%
-0.53
Dopo l'orario di chiusura:
51.35
-0.56
-1.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Precedente Chiudi:
$52.44
Aprire:
$53.07
Volume 24 ore:
6.54M
Relative Volume:
2.54
Capitalizzazione di mercato:
$13.05B
Reddito:
$2.38B
Utile/perdita netta:
$833.42M
Rapporto P/E:
17.20
EPS:
3.0172
Flusso di cassa netto:
$917.69M
1 W Prestazione:
-2.97%
1M Prestazione:
+4.15%
6M Prestazione:
+21.94%
1 anno Prestazione:
+27.42%
Intervallo 1D:
$50.96
$53.12
Intervallo di 1 settimana:
$50.96
$53.87
Portata 52W:
$33.76
$53.93
Exelixis Inc Stock (EXEL) Company Profile
Nome
Exelixis Inc
Settore
Industria
Telefono
(650) 837-7000
Indirizzo
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
51.91 | 13.05B | 2.38B | 833.42M | 917.69M | 3.0172 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-11-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Iniziato | Goldman | Buy |
| 2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2024-09-19 | Iniziato | UBS | Neutral |
| 2024-04-11 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Iniziato | BTIG Research | Buy |
| 2023-12-15 | Iniziato | Citigroup | Buy |
| 2023-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-22 | Reiterato | Oppenheimer | Outperform |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Ripresa | Piper Sandler | Overweight |
| 2023-03-09 | Iniziato | Wells Fargo | Overweight |
| 2023-01-26 | Iniziato | Credit Suisse | Outperform |
| 2022-10-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-03 | Ripresa | Jefferies | Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-18 | Ripresa | Goldman | Sell |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-03-18 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Iniziato | Goldman | Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Underweight |
| 2018-05-11 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-16 | Reiterato | SunTrust | Buy |
| 2017-09-22 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-12 | Reiterato | Needham | Buy |
| 2017-07-14 | Iniziato | SunTrust | Buy |
| 2017-03-31 | Iniziato | Needham | Buy |
| 2017-03-16 | Iniziato | Oppenheimer | Perform |
| 2017-02-28 | Downgrade | Stifel | Buy → Hold |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2016-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Reiterato | Stifel | Buy |
Mostra tutto
Exelixis Inc Borsa (EXEL) Ultime notizie
Exelixis Stockweekly review and biotech sector context - AD HOC NEWS
Here's why Exelixis (EXEL) is a strong momentum stock - MSN
Exelixis Inc (EXEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Exelixis Inc (EXEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Exelixis Inc (EXEL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Exelixis Inc (EXEL) Institutional Confidence - TradingKey
Exelixis Inc (EXEL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Exelixis Inc (EXEL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Exelixis Inc (EXEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Exelixis Inc (EXEL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Exelixis Inc (EXEL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Exelixis Inc Stock (US30161Q1040): Quarterly earnings in focus after recent results - AD HOC NEWS
Why (EXEL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Exelixis CABINET Win Extends CABOMETYX Reach And Raises Valuation Questions - Yahoo Finance
Exelixis, Inc. (EXEL) stock price, news, quote and history - Yahoo Finance UK
Exelixis, Inc. (EXEL) Latest Stock News & Headlines - Yahoo Finance
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight - GlobeNewswire Inc.
Exelixis Hits High on Growing Sales, Institutional Inflows - Yahoo Finance
Goldman Sachs Group Inc. Purchases 1,113,916 Shares of Exelixis, Inc. $EXEL - MarketBeat
Cibc World Market Inc. Purchases 31,985 Shares of Exelixis, Inc. $EXEL - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Has $1.91 Million Position in Exelixis, Inc. $EXEL - MarketBeat
Exelixis Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Exelixis stock hits all-time high at 52.98 USD By Investing.com - Investing.com Canada
Exelixis stock hits all-time high at 52.98 USD - Investing.com
Exelixis Inc (NASDAQ:EXEL) Offers Decent Value with Strong Profitability and Financial Health - ChartMill
Bank of New York Mellon Corp Cuts Position in Exelixis, Inc. $EXEL - MarketBeat
· Analyst Forecast - MLQ.ai
Exelixis, Inc. $EXEL Position Increased by Northwestern Mutual Wealth Management Co. - MarketBeat
Exelixis, Inc. (EXEL) Stock Analysis: A Promising Player in Biotechnology with Strong Revenue Growth - DirectorsTalk Interviews
Los Angeles Capital Management LLC Has $49.57 Million Holdings in Exelixis, Inc. $EXEL - MarketBeat
Commonwealth Equity Services LLC Sells 259,643 Shares of Exelixis, Inc. $EXEL - MarketBeat
168,437 Shares in Exelixis, Inc. $EXEL Purchased by WINTON GROUP Ltd - MarketBeat
Norges Bank Makes New Investment in Exelixis, Inc. $EXEL - MarketBeat
EULAV Asset Management Trims Stock Position in Exelixis, Inc. $EXEL - MarketBeat
CABINET Results Broaden CABOMETYX Neuroendocrine Reach And Investor Considerations - Sahm
Exelixis (NASDAQ:EXEL) Reaches New 52-Week HighTime to Buy? - MarketBeat
Why Exelixis (EXEL) is a top growth stock for the long term - MSN
Exelixis, Inc. (EXEL) latest stock news and headlines - Yahoo Finance UK
Exelixis, Inc. (EXEL) Stock Price, News, Quote & History - Yahoo Finance
Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term - Yahoo Finance
Marietta Investment Partners LLC Has $815,000 Stock Holdings in Exelixis, Inc. $EXEL - MarketBeat
EXEL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Understanding Momentum Shifts in (EXEL) - Stock Traders Daily
Insider Sell Alert: Jack Wyszomierski Sells 3,925 Shares of Exelixis Inc (EXEL) - GuruFocus
Exelixis Inc at Jefferies Global Healthcare Conference in New York Transcript - GuruFocus
Exelixis director Jack Wyszomierski sells $198,408 in shares By Investing.com - Investing.com Australia
Exelixis director Jack Wyszomierski sells $198,408 in shares - Investing.com UK
Exelixis director Sue Eckhardt sells $491,973 in stock - Investing.com UK
Exelixis director Sue Eckhardt sells $491,973 in stock By Investing.com - Investing.com Australia
Planned share sale by Exelixis (NASDAQ: EXEL) director Wyszomierski - Stock Titan
Exelixis Inc Azioni (EXEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):